Business
BetterLife Pharma Announces Appointment of Doug Drysdale as Executive Chairman and Director
Vancouver, British Columbia--(Newsfile Corp. - May 13, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biotech company, is pleased to announce it has appointed Doug Drysdale, currently BetterLife's corporate advisor and formerly CEO of Cybin Inc. ("Cybin") (NYSE: CYBN), as Executive Chairman and Director. At Cybin, Mr. Drysdale led the company's strategy and team build-out, taking it from molecule inception to Phase 3 trials in..
About this update from Betterlife Pharma Inc.
[{"type":"text","content":"Vancouver, British Columbia--(Newsfile Corp. - May 13, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biotech company, is pleased to announce it has appointed Doug Drysdale, currently BetterLife's corporate advisor and formerly CEO of Cybin Inc. ("Cybin") (NYSE: CYBN), as Executive Chairman and Director.","length":412,"tagName":"p"},{"type":"text","content":"At Cybin, Mr. Drysdale led the company's strategy and team build-out, taking it from molecule inception to Phase 3 trials in just three years. Mr. Drysdale is known as a vocal advocate for revolutionizing mental healthcare through numerous speaking engagements, panel participations, and media interviews.","length":309,"tagName":"p"},{"type":"text","content":""We are delighted to welcome Doug to our Board of Directors. His proven global leadership, underscored by a track record of executing multiple successful transactions across diverse markets and therapeutic indications, brings a depth of strategic insight and operational expertise that will meaningfully strengthen BetterLife", said Ahmad Doroudian, CEO of BetterLife. "Doug's experience navigating complex deal environments and scaling opportunities across jurisdictions will be invaluable as we continue to advance our growth strategy and create long-term shareholder value."","length":601,"tagName":"p"},{"type":"text","content":"Mr. Drysdale commented, "I am thrilled to join BetterLife as Executive Chairman and Director. Having led Cybin from molecule inception to Phase 3 trials in just three years, I look forward to bringing that same execution focus and global transaction expertise to accelerate BetterLife's growth strategy. Together with the team, we will continue to advance innovative therapies that target neurological disorders and deliver long-term value for patients and shareholders alike."","length":491,"tagName":"p"},{"type":"text","content":"Pursuant to the appointment of Mr. Drysdale as Executive Chairman, the Company has agreed to grant Mr. Drysdale stock options to purchase 3,500,000 common shares of BetterLife, with an exercise price of $0.065, monthly vesting over 24 months and a ten (10) year term.","length":267,"tagName":"p"},{"type":"text","content":"About Bett...